WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 5, 2017--
OvaScience℠ (NASDAQ: OVAS), a global fertility company focused on
the discovery, development and commercialization of new treatment
options, today announced that Michelle Dipp, M.D., Ph.D., Executive
Chair and Co-founder of OvaScience, will present a corporate overview at
the 35th Annual J.P. Morgan Healthcare Conference onThursday, January 12, 2017 at 8:30 a.m. PT (11:30 a.m. ET) at the Westin
St. Francis Hotel in San Francisco, California.
A live audio webcast of the presentation can be accessed by visiting the
investor section of the company’s website at www.ovascience.com.
A replay of the webcast will be archived on the OvaScience website for
30 days following the presentation.
OvaScience, Inc. (NASDAQ: OVAS) is a
global fertility company dedicated to improving treatment options for
women around the world. OvaScience is discovering, developing and
commercializing new fertility treatments because it believes women
deserve more options. Each OvaScience treatment is based on the
Company’s proprietary technology platform that leverages the
breakthrough discovery of egg precursor (EggPC℠) cells – immature egg
cells found inside the protective ovarian lining. OvaScience is
developing the OvaPrime℠treatment, which could increase a
woman’s egg reserve, and the OvaTure℠ treatment, a potential
next-generation IVF treatment that could help a woman produce healthy,
young, fertilizable eggs without hormone injections. OvaScience’s
AUGMENT℠ treatment, a fertility option designed to improve IVF success
rates, is available in certain IVF clinics in select international
regions. OvaScience treatments are not available in the U.S. For more
information, visit www.ovascience.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170105006300/en/
Source: OvaScience, Inc.
Jennifer Viera, 617-420-8748